In CRC, accumulating evidence has validated that the blockade of MCL-1 activity through pharmacological inhibition or degradation overcomes drug resistance and facilitates sensitization to targeted therapeutics [43,45,46,47,48,49]. The gene discussed is MCL1; the disease is colorectal carcinoma.